1. Scrip

Dosing Woes For VBI Vaccines As Share Price Plummets On Hep B Study Results

 
• By Jo Shorthouse

Despite positive results in the latest Phase III PROTECT study of its hepatitis B vaccine, VBI Vaccines failed to show non-inferiority at two doses, leaving it trailing behind competitor Dynavax and its established two-dose product.

Arch_Hands
The PROTECT study tested Sci-B-Vac against GSK's Engerix-B • Source: Shutterstock

Despite positive topline data, investors were unimpressed with the latest Phase III results from VBI Vaccines Inc.’s trials for its trivalent hepatitis B vaccine, causing the company's share price to drop by 66% on 17 June.

The Cambridge, MA-based firm released encouraging headline results from the pivotal Phase III study, PROTECT, designed to compare Sci-B-Vac with GlaxoSmithKline PLC’s vaccine Engerix-B. All patients in the Sci-B-Vac dose cohort received three 10mcg doses throughout the study, one each at months zero, one and six

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas